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Alzheimer’s Disease Today & Tomorrow
Sherry Shaffer, RN
Introduction
Alzheimer’s	Disease	(AD)	has	impacted	me	on	a	personal	level	and	professional	level.	I	
witnessed	my	grandfather	slowly	slip	away	at	the	hands	of	AD	over	the	course	of	a	decade.	As	
a	psychiatric	nurse,	I	have	provided	care	for	geriatric	patients	diagnosed	with	Alzheimer’s	
Disease	and	stuck	in	a	cycle	of	acute	psychiatric	distress	and	chronic	neurodegeneration.	
 Over	100	years	ago,	Dr.	Alois Alzheimer	first	described	AD.	(Alzheimer’s	
Association,	2016)
 In	1994,	former	President	Ronald	Reagan	put	AD	in	the	spotlight	when	he	publicly	
shared	his	diagnosis.	(Alzheimer’s	Association,	2016)
 In	2013,	the	CDC	estimates	as	many	as	5	million	Americans	suffered	from	AD.
 By	2050	a	nearly	three‐fold	increase	in	AD	cases	will	impact	14	million	Americans	
(CDC,	2015).	
The	progress	and	impact	of	AD	research	can	be	as	slow	as	the	pathophysiologic	changes	in	
the	brain	of	an	Alzheimer’s	patient.	So	where	are	we	today	and	where	will	we	be	tomorrow,	in	
relation	to	Alzheimer’s	Disease?
Signs & Symptoms
Preclinical,	asymptomatic	period	may	occur	years	before	the	early	stage	of	AD,	but	
pathophysiologic	changes	in	the	brain	are	probable	during	this	time	(Harvard,	2011).
Three	Disease	Stages	(Alzheimer’s	Association,	2016):
1. Mild	Alzheimer's	disease	(early‐stage)‐ mild	memory	and	thinking	deficits
2. Moderate	Alzheimer's	disease	(middle‐stage)‐ longest	stage	with	progressive	
memory	and	cognitive	deficits,	behavioral	and	personality	changes
3. Severe	Alzheimer's	disease	(late‐stage)‐ continued	worsening	of	cognitive	
deficits	until	total	loss	of	cognition	and	executive	functioning,	along	with	
personality	changes	and	inability	to	function	independently
Ten	Early	Signs	of	Alzheimer’s	(Alzheimer’s	Association,	2016):
1. Memory	loss	that	disrupts	daily	life	
2. Difficulty	with	problem‐solving	&	planning
3. Problems	completing	familiar	tasks
4. Confusion	with	time	or	place
5. Trouble	understanding	special	relationships	&	visual	images
6. New	problems	with	speech	&	written	vocabulary
7. Misplacing	items	&	inability	to	retrace	steps
8. Decreased	or	poor	judgment
9. Withdrawal	from	activities	
10. Changes	in	personality	& mood
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Implications for Nursing Care
There	is	no	cure	for	Alzheimer’s	disease	and	treatment	is	typically	focused	on	decreasing	
cognitive	impairments	and	preserving	cognitive	function	while	promoting	good	overall	
health	and	well‐being	(Narin,	2012).	Nurses	tend	to	be	on	the	front	line	for	medical	care	
and	patient	education.	Knowledge	of	the	disease	process,	current	and	developing	
treatments	and	patient	preferences	are	important	factors	for	nursing	care.	
Early	patient	education	focused	on	preventative	measure	and	overall	good	health	may	be	
beneficial.	Studies	have	shown	that	diet	and	modifiable	lifestyle	factors	are	associated	with	
risk	for	AD	and	include,	obesity,	diabetes,	hypertension,	and	hyperlipidemia	(Thomas,	
2015).	Nutritional	education	is	particularly	important	for	AD	patients	as	they	are	often	
malnourished	and	have	nutrient	deficiencies	(Thomas,	2015).	Observational	studies	and	
controlled	trials	indicate	that	regular	physical	activity	can	lessen	the	risk	for	cognitive	
decline	in	the	elderly	and	yoga	practice	may	be	beneficial	in	memory	and	cognitive	function	
and	in	turn	helpful	in	the	management	of	AD	(Bhargav,	2015).
Research	has	been	focused	on	modifying	the	progression	of	the	disease,	while	
developments	in	diagnostic	biomarkers,	proteomics	and	neuroimaging	may	assist	in	earlier	
diagnosis	and	treatment	and	detection	of	high	risk	individuals	(Brodaty,	et.	Al,	2011).	In	
turn,	clinicians	may	see	more	patients	with	definitive	AD	diagnosis	while	at	a	higher	level	
of	cognitive	functioning	than	typically	seen	today	(Brodaty,	et.	Al,	2011).	Often	clinicians	
turn	to	an	AD	patient’s	caregiver	for	assessment	information,	despite	the	fact	that	
individuals	with	dementia	can	provide	reliable	and	meaningful	reports	(Mast,	2012).
Integrating	person‐centered	care	with	diagnostic	assessments	and	treatment	planning	can	
improve	the	quality	of	care	and	quality	of	life	for	patients	dealing	with	this	devastating	
disease.	When	used	properly,	the	following	supplemental	assessment	tools	can	provide	
valuable	information	to	clinicians,	while	taking	a	person‐centered	approach	and	building	a	
therapeutic	relationship	with	the	patient	(Mast	2012).
 Quality	of	Life	(QOL)‐ AD	Scale
 Pleasant	Events	Schedule	(shorter	version	for	AD)
 Alzheimer’s	Disease	Knowledge	Scale
 Fear	of	Alzheimer’s	Disease	Scale	(FADS)
 Stigma	Impact	Scale	(SIS)
 Values	and	Preferences	Scale
Conclusions
As	Alzheimer’s	disease	exponentially	impacts	more	lives	and	our	nation’s	economy,	we	as	
clinicians	need	to	be	ready	to	think	outside	the	box.	We	must	stay	abreast	of	current	and	
developing	diagnosis	assessment	tools,	treatment	options	and	interventions.	It	is	not	
enough	to	simply	maintain	a	person’s	existence	through	the	years	and	even	decade	or	more	
of	an	Alzheimer’s	diagnosis.	Despite	the	loss	of	memory,	despite	the	loss	of	functioning,	
there	is	a	person	inside	the	shell	that	has	been	left	behind	by	this	devastating	disease.	A	
person	that	has	touch	the	lives	of	his	or	her	family	and	friends	and	deserves	the	same	
amount	of	consideration	and	care	as	a	patient	fighting	cancer,	heart	disease	or	diabetes.
*Images retrieved from :
Renegadehealth.com
Medicinenet.com
Underlying Pathophysiology
Inflammation	and	ischemia	of	the	brain	may	influence	the	development	of	beta‐amyloid	plaques	and	
neurofibrillary	tangles	associated	with	AD	(Narins,	2012).	Free	radical	damage	through	oxidative	
processes	have	been	known	to	damage	brain	cells	(Narins,	2012).	Research	as	identified	a	link	between	
memory	deficits	and	integrated	neuronal	cortical	defects	(Lyketsos,	2012).	While	viral,	immunological,	
and	biochemical	factors	have	been	noted	as	causative	suspects,	genetics	are	implicated	in	familial	
Alzheimer’s	disease	(FAD)	early‐ onset	and	late‐ onset	Alzheimer’s	disease,	although	to	a	much	lesser	
extent	(Narins,	2012).	Genetic	defects	linked	with	AD	include:
 Amyloid	precursor	protein	(APP)	on	chromosome	21
 Presenilin 1	(PSEN1)	on	chromosome	14
 Presenilin 2	(PSEN2)	on	chromosome	1
 Apolipoprotein	E	gene‐allele	4	(apoE4)	on	chromosome	19
The	precise	cause	of	AD	is	unknown,	but	the	leading	theory	of	the	disease	process	includes	the	following	
(Narin,	2012):
 Collection	of	beta‐amyloid	protein	plaques	outside	neurons
 Tau	protein	form	neurofibrillary	tangles	inside	neurons
 Loss	of	synaptic	function
 Destruction	of	neurons	&	brain	tissue
 Widening	of	sulci
 Thinning	of	gyri
 Enlarged	ventricles
Significance of Pathophysiology
The	significance	of	Alzheimer’s	pathophysiology	can	be	seen	as	the	disease	progresses	and	specific	areas	
of	the	brain	atrophies,	resulting	in	deterioration	of	patient	functioning	(Narin,	2012):	
 Hippocampus	>>>	memory	(specifically	short‐term)	decline
 Cerebral	cortex	>>>	language,	judgment,	behavior,	and	body	functions	decline
 Posterior	frontal	lobes	>>>	motor	issues,	hypertonicity
 Brain	stem	>>>	loss	of	vital	functioning	(digestion,	respiration	and	excretion)
Other	significant	consequences	of	AD	pathophysiology	include	vision	problems,	exaggerated	reflexes	and	
seizures	putting	patients	at	risk	for	falls	and	injuries	(Narin,	2012).	Spatial	and	temporal	disorientation	
may	result	in	psychotic‐like	symptoms	such	as	delusions,	paranoia	and	hallucinations	(Narin,	2012).	Some	
patients	may	exhibit	sexually	inappropriate	behaviors,	and	others	may	experience	insomnia	with	
nighttime	confusion	or	agitation	known	as	sundowner’s	syndrome	(Narin,	2012).	As	the	disease	
progresses,	so	does	the	patient’s	loss	of	independence.	Patients	become	at	greater	risk	for	harm	to	
themselves	and	in	some	cases	others.
